🚀 VC round data is live in beta, check it out!
XSpray Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for XSpray Pharma and similar public comparables like Aardvark Therapeutics, OSE Immunotherapeutics, Cardiol Therapeutics, Darya-Varia Laboratoria and more.
XSpray Pharma Overview
About XSpray Pharma
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.
Founded
2003
HQ
Employees
27
Website
Sectors
Financials (LTM)
EV
$111M
XSpray Pharma Financials
XSpray Pharma reported last 12-month revenue of $2M and negative EBITDA of ($19M).
In the same LTM period, XSpray Pharma generated ($19M) in EBITDA losses.
Revenue (LTM)
XSpray Pharma P&L
In the most recent fiscal year, XSpray Pharma reported revenue of — and EBITDA of ($16M).
XSpray Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | — | XXX | XXX | XXX |
| EBITDA | ($19M) | XXX | ($16M) | XXX | XXX | XXX |
| EBITDA Margin | (812%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (836%) | XXX | — | XXX | XXX | XXX |
| Net Profit | — | XXX | ($18M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
XSpray Pharma Stock Performance
XSpray Pharma has current market cap of $112M, and enterprise value of $111M.
Market Cap Evolution
XSpray Pharma's stock price is $2.68.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $111M | $112M | -0.9% | XXX | XXX | XXX | $-0.43 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialXSpray Pharma Valuation Multiples
XSpray Pharma trades at 46.6x EV/Revenue multiple, and (5.7x) EV/EBITDA.
EV / Revenue (LTM)
XSpray Pharma Financial Valuation Multiples
As of April 2, 2026, XSpray Pharma has market cap of $112M and EV of $111M.
Equity research analysts estimate XSpray Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
XSpray Pharma has a P/E ratio of (6.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $112M | XXX | $112M | XXX | XXX | XXX |
| EV (current) | $111M | XXX | $111M | XXX | XXX | XXX |
| EV/Revenue | 46.6x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (5.7x) | XXX | (7.1x) | XXX | XXX | XXX |
| EV/EBIT | (5.6x) | XXX | (6.7x) | XXX | XXX | XXX |
| P/E | — | XXX | (6.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified XSpray Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
XSpray Pharma Margins & Growth Rates
XSpray Pharma's revenue in the last 12 month grew by 870%.
XSpray Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.6M for the same period.
XSpray Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 870% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (812%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | (19%) | XXX | 70% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
XSpray Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Aardvark Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| OSE Immunotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cardiol Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Darya-Varia Laboratoria | XXX | XXX | XXX | XXX | XXX | XXX |
| Precision BioSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
XSpray Pharma M&A Activity
XSpray Pharma acquired XXX companies to date.
Last acquisition by XSpray Pharma was on XXXXXXXX, XXXXX. XSpray Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by XSpray Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialXSpray Pharma Investment Activity
XSpray Pharma invested in XXX companies to date.
XSpray Pharma made its latest investment on XXXXXXXX, XXXXX. XSpray Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by XSpray Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout XSpray Pharma
| When was XSpray Pharma founded? | XSpray Pharma was founded in 2003. |
| Where is XSpray Pharma headquartered? | XSpray Pharma is headquartered in Sweden. |
| How many employees does XSpray Pharma have? | As of today, XSpray Pharma has over 27 employees. |
| Who is the CEO of XSpray Pharma? | XSpray Pharma's CEO is Per Andersson. |
| Is XSpray Pharma publicly listed? | Yes, XSpray Pharma is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of XSpray Pharma? | XSpray Pharma trades under XSPRAY ticker. |
| When did XSpray Pharma go public? | XSpray Pharma went public in 2017. |
| Who are competitors of XSpray Pharma? | XSpray Pharma main competitors are Aardvark Therapeutics, OSE Immunotherapeutics, Cardiol Therapeutics, Darya-Varia Laboratoria. |
| What is the current market cap of XSpray Pharma? | XSpray Pharma's current market cap is $112M. |
| What is the current revenue of XSpray Pharma? | XSpray Pharma's last 12 months revenue is $2M. |
| What is the current revenue growth of XSpray Pharma? | XSpray Pharma revenue growth (NTM/LTM) is 870%. |
| What is the current EV/Revenue multiple of XSpray Pharma? | Current revenue multiple of XSpray Pharma is 46.6x. |
| Is XSpray Pharma profitable? | No, XSpray Pharma is not profitable. |
| What is the current EBITDA of XSpray Pharma? | XSpray Pharma has negative EBITDA and is not profitable. |
| What is XSpray Pharma's EBITDA margin? | XSpray Pharma's last 12 months EBITDA margin is (812%). |
| What is the current EV/EBITDA multiple of XSpray Pharma? | Current EBITDA multiple of XSpray Pharma is (5.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.